Supriya Lifescience Limited executed a long-term Supply and Sales Agreement (hereinafter "Agreement") on May 23, 2023, with a leading Company in Europe for the supply of Active Pharmaceutical Ingredient (API) for a period of 10 years. The business potential would be approximately INR 400 Million per year at its peak. The peak volumes are expected to happen in Fiscal Year 27.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
377.6 INR | -0.32% | -1.73% | +19.98% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.98% | 37Cr | |
+32.36% | 71TCr | |
+30.77% | 60TCr | |
-1.60% | 37TCr | |
+20.07% | 33TCr | |
+6.04% | 29TCr | |
+14.77% | 24TCr | |
+9.13% | 21TCr | |
-3.97% | 20TCr | |
+9.27% | 17TCr |
- Stock Market
- Equities
- SUPRIYA Stock
- News Supriya Lifescience Limited
- Supriya Lifescience Limited Executes A Long-Term Supply and Sales Agreement with A Leading Company in Europe for the Supply of Active Pharmaceutical Ingredient